Halozyme Therapeutics, Inc. (HALO)

In the past six months, Halozyme's stock has trended upwards by 33.22%. Key events impacting the stock price include strong Q3 2025 earnings, the acquisition of Elektrofi, a collaboration with Merus, FDA approval for DARZALEX Faspro, and analyst adjustments. Goldman Sachs and Citizens raised their price targets on HALO, while Zacks Research decreased its Q4 2025 earnings per share estimates. Insiders sold approximately 110,227 shares, and Halozyme announced a CFO transition plan.

Based on the available information, there is no explicit indication of significant demand seasonality for Halozyme Therapeutics, Inc.'s products and services. The company's revenue is primarily derived from royalties on partnered products and sales of its own products. The demand for pharmaceutical products typically exhibits less seasonality compared to consumer goods.

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on oncology therapies, researching, developing, and commercializing proprietary enzymes and devices. Its core business is the ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of injectable biologics. Halozyme licenses its ENHANZE technology to other biopharmaceutical companies, with major products including Darzalex SC, Phesgo, Vyvgart, Vyvgart Hytrulo, Opdivo (Qvantiq), Ocrevus (Zunovo), and Tecentriq Hybreza. The company also has an FDA-approved product called Hylenex recombinant and is developing PEGPH20 for hyaluronan (HA) high tumors. Halozyme acquired Elektrofi to expand its drug delivery offerings.

Halozyme Therapeutics, Inc. is headquartered in San Diego, California, United States, and conducts its research, development, and commercialization activities in the United States and internationally. The company has minimal long-lived assets located internationally. Halozyme's stock is listed on several international exchanges in addition to NASDAQ.

Halozyme Therapeutics has maintained a generally positive brand reputation over the past year, driven by its innovative enzyme technology, strategic collaborations, and strong financial performance. Regulatory approvals, consistent earnings beats, and strategic acquisitions have positively impacted its reputation. However, there are long-term concerns regarding the uncertainty of post-2027 growth due to the expiration of the core U.S. patent for its ENHANZE technology.

Halozyme Therapeutics, Inc. is predominantly owned by institutional shareholders, who hold between approximately 71.25% and 101.31% of the company's stock. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and State Street Corp. Individual insiders own approximately 1.06% to 29.44% of the company, with Randal J. Kirk being the largest individual shareholder. Retail investors hold between 0.00% and 27.60% of the stock.